• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)

    2/12/24 6:19:50 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HALO alert in real time by email
    SC 13G/A 1 d754689dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c)

    and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2.

    Under the Securities Exchange Act of 1934

    (Amendment No. 4 )*

     

     

    Halozyme Therapeutics, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    40637H109

    (CUSIP Number)

    12/31/2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒

    Rule 13d-1(b)

     

      ☐

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 40637H109    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Limited Partnership

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     None

       6   

     SHARED VOTING POWER

     

     5,896,607

       7   

     SOLE DISPOSITIVE POWER

     

     None

       8   

     SHARED DISPOSITIVE POWER

     

     6,689,058

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,689,058

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     

     ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.1%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     IA

     


    CUSIP No. 40637H109    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Investments GP LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     None

       6   

     SHARED VOTING POWER

     

     5,896,607

       7   

     SOLE DISPOSITIVE POWER

     

     None

       8   

     SHARED DISPOSITIVE POWER

     

     6,689,058

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,689,058

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     

     ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.1%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC

     


    CUSIP No. 40637H109    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Holdings LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     None

       6   

     SHARED VOTING POWER

     

     5,896,607

       7   

     SOLE DISPOSITIVE POWER

     

     None

       8   

     SHARED DISPOSITIVE POWER

     

     6,689,058

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,689,058

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     

     ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.1%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC


    CUSIP No. 40637H109    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Asset Management Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     None

       6   

     SHARED VOTING POWER

     

     5,896,607

       7   

     SOLE DISPOSITIVE POWER

     

     None

       8   

     SHARED DISPOSITIVE POWER

     

     6,689,058

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,689,058

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     

     ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.1%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC


    Item 1(a)

    Name of Issuer:

    Halozyme Therapeutics, Inc.

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    12390 El Camino Real, San Diego, California 92130

     

    Item 2(a)

    Name of Person Filing:

    Artisan Partners Limited Partnership (“APLP”)

    Artisan Investments GP LLC (“Artisan Investments”)

    Artisan Partners Holdings LP (“Artisan Holdings”)

    Artisan Partners Asset Management Inc. (“APAM”)

     

    Item 2(b)

    Address of Principal Business Office:

    APLP, Artisan Investments, Artisan Holdings, and APAM are all located at:

    875 East Wisconsin Avenue, Suite 800

    Milwaukee, WI 53202

     

    Item 2(c)

    Citizenship:

    APLP is a Delaware limited partnership

    Artisan Investments is a Delaware limited liability company

    Artisan Holdings is a Delaware limited partnership

    APAM is a Delaware corporation

     

    Item 2(d)

    Title of Class of Securities:

    Common Stock

     

    Item 2(e)

    CUSIP Number:

    40637H109

     

    Item 3

    Type of Person:

    (e) APLP is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

    (g) Artisan Holdings is the sole limited partner of APLP and the sole member of Artisan Investments; Artisan Investments is the general partner of APLP; APAM is the general partner of Artisan Holdings.


    Item 4

    Ownership (at 12/31/2023):

     

      (a)

    Amount owned “beneficially” within the meaning of rule 13d-3:

    6,689,058

     

      (b)

    Percent of class:

    5.1% (based on 132,098,110 shares outstanding as of 10/31/2023)

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or to direct the vote: None

     

      (ii)

    shared power to vote or to direct the vote: 5,896,607

     

      (iii)

    sole power to dispose or to direct the disposition of: None

     

      (iv)

    shared power to dispose or to direct the disposition of: 6,689,058

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    Not Applicable

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    The shares reported herein have been acquired on behalf of discretionary clients of APLP. Persons other than APLP are entitled to receive all dividends from, and proceeds from the sale of, those shares. None of those persons, to the knowledge of APLP, Artisan Holdings, APAM, or Artisan Investments has an economic interest in more than 5% of the class.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not Applicable

     

    Item 8

    Identification and Classification of Members of the Group:

    Not Applicable

     

    Item 9

    Notice of Dissolution of Group:

    Not Applicable

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: 2/12/2024

     

    ARTISAN PARTNERS ASSET MANAGEMENT INC,
    for itself and as the general partner of
    ARTISAN PARTNERS HOLDINGS LP
    By:   Gregory K. Ramirez *
    ARTISAN INVESTMENTS GP LLC,
    for itself and as the general partner of
    ARTISAN PARTNERS LIMITED PARTNERSHIP
    By:   Gregory K. Ramirez *
    *By:   /s/ Gregory K. Ramirez
      Gregory K. Ramirez
      Executive Vice President of Artisan Partners Asset Management Inc.
      Vice President of Artisan Investments GP LLC


    Exhibit Index

     

    Exhibit 1    Joint Filing Agreement dated 2/12/2024 by and among Artisan Partners Limited Partnership, Artisan Investments GP LLC, Artisan Partners Holdings LP, and Artisan Partners Asset Management Inc.
    Get the next $HALO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HALO

    DatePrice TargetRatingAnalyst
    5/14/2025$62.00Overweight → Equal-Weight
    Morgan Stanley
    5/13/2025$47.00Market Perform → Underperform
    Leerink Partners
    10/7/2024$58.00 → $62.00Overweight → Equal Weight
    Wells Fargo
    9/19/2024$52.00 → $57.00Overweight → Neutral
    JP Morgan
    6/7/2024$48.00 → $51.00Overweight → Neutral
    Piper Sandler
    2/29/2024$54.00Outperform
    TD Cowen
    7/24/2023$61.00Buy
    H.C. Wainwright
    7/24/2023$43.00 → $45.00Buy → Neutral
    Goldman
    More analyst ratings

    $HALO
    Financials

    Live finance-specific insights

    See more
    • HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

      Announcing New $250M Share Repurchase  Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 SAN DIEGO, May 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Hal

      5/6/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Report First Quarter 2025 Financial and Operating Results

      SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813723. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advanci

      4/28/25 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

      Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.261 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to $632 million and non-GAAP EPS Increased 53% YOY to $4.231, Both Exceeding Guidance  Reiterating 2025 Finan

      2/18/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Halozyme Therapeutics Inc.

      SCHEDULE 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      5/13/25 11:18:25 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Halozyme Therapeutics Inc.

      10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

      5/6/25 4:08:30 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

      5/6/25 4:06:31 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Posard Matthew L. was granted 4,165 shares, increasing direct ownership by 6% to 74,039 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:11:14 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Miyashita Akiko Moni was granted 4,165 shares, increasing direct ownership by 20% to 24,937 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:09:44 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Krishnan Mahesh was granted 4,165 shares, increasing direct ownership by 64% to 10,666 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:08:05 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $HALO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Halozyme Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Halozyme Therapeutics from Overweight to Equal-Weight and set a new price target of $62.00

      5/14/25 8:56:30 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Halozyme Therapeutics from Market Perform to Underperform and set a new price target of $47.00

      5/13/25 8:55:01 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Halozyme Therapeutics from Overweight to Equal Weight and set a new price target of $62.00 from $58.00 previously

      10/7/24 8:32:56 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Halozyme Therapeutics Inc.

      SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      11/12/24 9:36:57 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Halozyme Therapeutics Inc.

      SC 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      10/17/24 9:36:19 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)

      SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      2/13/24 5:06:13 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

      Announcing New $250M Share Repurchase  Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 SAN DIEGO, May 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Hal

      5/6/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

      SAN DIEGO, May 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET. A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the

      5/5/25 5:15:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Report First Quarter 2025 Financial and Operating Results

      SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813723. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advanci

      4/28/25 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Leadership Updates

    Live Leadership Updates

    See more
    • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

      KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

      9/4/24 8:00:00 AM ET
      $AVTX
      $DRRX
      $HALO
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medicinal Chemicals and Botanical Products
    • Mahesh Krishnan Elected to Halozyme's Board of Directors

      SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies." Dr.

      4/25/24 4:45:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Appoints Barbara Duncan to its Board of Directors

      SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry. "We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance experience to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Barbara's business leadership, financial expertise and board experience will add important insights and contributions to the continuing success and growth of the company." Ms. Duncan

      2/6/23 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care